Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Stability and suitability for storage and distribution of Ad26.ZEBOV/MVA-BN®-Filo heterologous prime-boost Ebola vaccine.

Capelle MAH, Babich L, van Deventer-Troost JPE, Salerno D, Krijgsman K, Dirmeier U, Raaby B, Adriaansen J.

Eur J Pharm Biopharm. 2018 Aug;129:215-221. doi: 10.1016/j.ejpb.2018.06.001. Epub 2018 Jun 2.

PMID:
29870747
2.

Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.

Shah K, Bentley E, Tyler A, Richards KSR, Wright E, Easterbrook L, Lee D, Cleaver C, Usher L, Burton JE, Pitman JK, Bruce CB, Edge D, Lee M, Nazareth N, Norwood DA, Moschos SA.

Chem Sci. 2017 Nov 1;8(11):7780-7797. doi: 10.1039/c7sc03281a. Epub 2017 Sep 25.

3.

[The effect of some physical and chemical factors on inactivation of the Ebola virus].

Chepurnov AA, Chuev IuP, P'iankov OV, Efimova IV.

Vopr Virusol. 1995 Mar-Apr;40(2):74-6. Russian.

PMID:
7762236

Supplemental Content

Loading ...
Support Center